{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T23:33:52Z","timestamp":1776814432505,"version":"3.51.2"},"reference-count":30,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bioorganic & Medicinal Chemistry Letters"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.bmcl.2023.129144","type":"journal-article","created":{"date-parts":[[2023,1,18]],"date-time":"2023-01-18T15:35:51Z","timestamp":1674056151000},"page":"129144","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Synthesis and biological evaluation of novel aromatic amide derivatives as potential BCR-ABL inhibitors"],"prefix":"10.1016","volume":"81","author":[{"given":"Xiujun","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhou","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gang","family":"Pan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xingbei","family":"He","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingxiao","family":"Lv","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huijie","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wentao","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5569-245X","authenticated-orcid":false,"given":"Jing","family":"Ji","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mingli","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bmcl.2023.129144_b0005","doi-asserted-by":"crossref","first-page":"3029","DOI":"10.1002\/cncr.33587","article-title":"The ever-increasing importance of cancer as a leading cause of premature death worldwide","volume":"127","author":"Bray","year":"2021","journal-title":"Cancer"},{"key":"10.1016\/j.bmcl.2023.129144_b0010","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA: Cancer J Clin"},{"key":"10.1016\/j.bmcl.2023.129144_b0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40164-020-00170-6","article-title":"Leukemia incidence trends at the global, regional, and national level between 1990 and 2017","volume":"9","author":"Dong","year":"2020","journal-title":"Exp Hematol Oncol"},{"key":"10.1016\/j.bmcl.2023.129144_b0020","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","article-title":"A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining","volume":"243","author":"Rowley","year":"1973","journal-title":"Nature"},{"key":"10.1016\/j.bmcl.2023.129144_b0025","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1056\/NEJM198810133191506","article-title":"The molecular genetics of Philadelphia chromosome\u2013positive leukemias","volume":"319","author":"Kurzrock","year":"1988","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bmcl.2023.129144_b0030","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1016\/S0140-6736(21)01204-6","article-title":"Chronic myeloid leukaemia","volume":"398","author":"Cortes","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.bmcl.2023.129144_b0035","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/leu.2009.38","article-title":"Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia","volume":"23","author":"Hochhaus","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.bmcl.2023.129144_b0040","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1002\/ajh.22037","article-title":"Progressive peripheral arterial occlusive disease and other vascular events during nilotinib therapy in CML","volume":"86","author":"Aichberger","year":"2011","journal-title":"Am J Hematol"},{"key":"10.1016\/j.bmcl.2023.129144_b0045","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1093\/jnci\/djr060","article-title":"Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib","volume":"103","author":"Gambacorti-Passerini","year":"2011","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.bmcl.2023.129144_b0050","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.3324\/haematol.2015.129221","article-title":"Long-term outcome of a phase 2 trial with nilotinib 400 mg twice daily in first-line treatment of chronic myeloid leukemia","volume":"100","author":"Gugliotta","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.bmcl.2023.129144_b0055","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1002\/ajh.22051","article-title":"Nilotinib treatment-associated peripheral artery disease and sudden death: yet another reason to stick to imatinib as front-line therapy for chronic myelogenous leukemia","volume":"86","author":"Tefferi","year":"2011","journal-title":"Am J Hematol"},{"key":"10.1016\/j.bmcl.2023.129144_b0060","doi-asserted-by":"crossref","first-page":"4701","DOI":"10.1021\/jm100395q","volume":"53","author":"Huang","year":"2010","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2023.129144_b0065","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V128.22.3055.3055","article-title":"Ponatinib and cardiovascular complications","volume":"128","author":"Schmaier","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.bmcl.2023.129144_b0070","doi-asserted-by":"crossref","first-page":"8120","DOI":"10.1021\/acs.jmedchem.8b01040","article-title":"Discovery of asciminib (ABL001), an allosteric inhibitor of the tyrosine kinase activity of BCR-ABL1","volume":"61","author":"Schoepfer","year":"2018","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2023.129144_b0075","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/nature21702","article-title":"The allosteric inhibitor ABL001 enables dual targeting of BCR-ABL1","volume":"543","author":"Wylie","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.bmcl.2023.129144_b0080","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/s42003-020-01508-w","article-title":"NTRK kinase domain mutations in cancer variably impact sensitivity to type I and type II inhibitors","volume":"3","author":"Somwar","year":"2020","journal-title":"Commun Biol."},{"key":"10.1016\/j.bmcl.2023.129144_b0085","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1107\/S0907444906047287","article-title":"Structural biology contributions to the discovery of drugs to treat chronic myelogenous leukaemia","volume":"63","author":"Cowan-Jacob","year":"2007","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"key":"10.1016\/j.bmcl.2023.129144_b0090","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1042\/BJ20141492","article-title":"Crystal structure of an SH2\u2013kinase construct of c-Abl and effect of the SH2 domain on kinase activity","volume":"468","author":"Lorenz","year":"2015","journal-title":"Biochem J"},{"key":"10.1016\/j.bmcl.2023.129144_b0095","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/nature21702","article-title":"The allosteric inhibitor ABL001 enables dual targeting of BCR\u2013ABL1","volume":"543","author":"Wylie","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.bmcl.2023.129144_b0100","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1021\/acs.jmedchem.6b01290","article-title":"Discovery of 4-Methyl-N-(4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)phenyl)-3-((1-n icotinoylpiperidin-4-yl)oxy)benzamide (CHMFL-ABL\/KIT-155) as a novel highly potent Type II ABL\/KIT dual kinase inhibitor with a distinct hinge binding","volume":"60","author":"Wang","year":"2017","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2023.129144_b0105","doi-asserted-by":"crossref","first-page":"5793","DOI":"10.1016\/j.bmcl.2004.09.042","article-title":"Urea derivatives of STI571 as inhibitors of Bcr-Abl and PDGFR kinases","volume":"14","author":"Manley","year":"2004","journal-title":"Bioorg Med Chem Lett"},{"key":"10.1016\/j.bmcl.2023.129144_b0110","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ccr.2005.01.007","article-title":"Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl","volume":"7","author":"Weisberg","year":"2005","journal-title":"Cancer Cell"},{"key":"10.1016\/j.bmcl.2023.129144_b0115","doi-asserted-by":"crossref","first-page":"1522","DOI":"10.1039\/C4RA11183D","article-title":"An efficient d-glucosamine-based copper catalyst for C-X couplings and its application in the synthesis of nilotinib intermediate","volume":"5","author":"Wen","year":"2015","journal-title":"RSC Adv"},{"key":"10.1016\/j.bmcl.2023.129144_b0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2020.115344","article-title":"A small molecule inhibitor of PCSK9 that antagonizes LDL receptor binding via interaction with a cryptic PCSK9 binding groove","volume":"28","author":"Evison","year":"2020","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.bmcl.2023.129144_b0125","doi-asserted-by":"crossref","first-page":"2121","DOI":"10.1055\/s-2007-983754","article-title":"An efficient synthesis of nilotinib (AMN107)","volume":"2007","author":"Huang","year":"2007","journal-title":"Synthesis"},{"key":"10.1016\/j.bmcl.2023.129144_b0130","doi-asserted-by":"crossref","first-page":"4743","DOI":"10.1021\/jm900166t","article-title":"9-(Arenethenyl) purines as dual Src\/Abl kinase inhibitors targeting the inactive conformation: design, synthesis, and biological evaluation","volume":"52","author":"Huang","year":"2009","journal-title":"J Med Chem"},{"key":"10.1016\/j.bmcl.2023.129144_b0135","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1002\/cmdc.201700044","article-title":"Novel pieces for the emerging picture of sulfoximines in drug discovery: synthesis and evaluation of sulfoximine analogues of marketed drugs and advanced clinical candidates","volume":"12","author":"Sirvent","year":"2017","journal-title":"ChemMedChem"},{"key":"10.1016\/j.bmcl.2023.129144_b0140","doi-asserted-by":"crossref","first-page":"3920","DOI":"10.1021\/ol301673q","article-title":"A \u201cCatch\u2013React\u2013Release\u201d method for the flow synthesis of 2-aminopyrimidines and preparation of the imatinib base","volume":"14","author":"Ingham","year":"2012","journal-title":"Org Lett"},{"key":"10.1016\/j.bmcl.2023.129144_b0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114372","article-title":"Design, synthesis, and biological evaluation of novel diphenylamine derivatives as tubulin polymerization inhibitors targeting the colchicine binding site","volume":"237","author":"Yan","year":"2022","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.bmcl.2023.129144_b0150","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0092-8674(00)80434-1","article-title":"Cytochrome c and dATP-dependent formation of Apaf-1\/caspase-9 complex initiates an apoptotic protease cascade","volume":"91","author":"Li","year":"1997","journal-title":"Cell"}],"container-title":["Bioorganic & Medicinal Chemistry Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X23000227?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0960894X23000227?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T07:46:37Z","timestamp":1760773597000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0960894X23000227"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":30,"alternative-id":["S0960894X23000227"],"URL":"https:\/\/doi.org\/10.1016\/j.bmcl.2023.129144","relation":{},"ISSN":["0960-894X"],"issn-type":[{"value":"0960-894X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Synthesis and biological evaluation of novel aromatic amide derivatives as potential BCR-ABL inhibitors","name":"articletitle","label":"Article Title"},{"value":"Bioorganic & Medicinal Chemistry Letters","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bmcl.2023.129144","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"129144"}}